According to Aclaris Therapeutics's latest financial reports the company has HK$0.99 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | HK$0.93 B | -45.28% |
2022-12-31 | HK$1.69 B | 13.89% |
2021-12-31 | HK$1.49 B | 255.68% |
2020-12-31 | HK$0.41 B | -26.46% |
2019-12-31 | HK$0.57 B | -56.62% |
2018-12-31 | HK$1.31 B | -13.15% |
2017-12-31 | HK$1.51 B | 42.34% |
2016-12-31 | HK$1.06 B | 61.77% |
2015-12-31 | HK$0.65 B | 425.76% |
2014-12-31 | HK$0.12 B | 21.09% |
2013-12-31 | HK$0.10 B |